• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,068.45 1,372.06
( 1.89%)
Global Indices
Nasdaq
46,234.46 635.98
(1.39%)
Dow Jones
6,603.33 75.85
(1.16%)
Hang Seng
52,101.04 585.55
(1.14%)
Nikkei 225
9,942.10 47.95
(0.48%)
Forex
USD-INR
93.49 0.36
(0.39%)
EUR-INR
108.15 0.98
(0.91%)
GBP-INR
124.68 0.54
(0.44%)
JPY-INR
0.59 0.00
(0.10%)

EQUITY - MARKET SCREENER

TPL Plastech Ltd
Industry :  Packaging
BSE Code
ISIN Demat
Book Value()
526582
INE413G01022
19.5030832
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TPLPLASTEH
16.04
446.72
EPS(TTM)
Face Value()
Div & Yield %
3.57
2
1.75
 

simplex papers ltd
Marksans Pharma’s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
Nov 19,2025

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).

Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma’s portfolio in the US generic pharmaceutical market.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.

Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.